GlassScriptPhysician profile
Matthew Hislop
NPI 1174062491
$9,708.35
in general payments reported to CMS, 2019-2025
31 companies · $3,054 in 2025
The $3,054 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $963 · 2022: $2,775 · 2023: $1,111 · 2024: $1,805 · 2025: $3,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,633 · Education: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,633.27 |
| Education | $336.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,998.12 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,024.83 | 2021-2025 | Winlevi, Absorica Ld, Blu-U |
| Janssen Biotech, INC. | $937.06 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $816.58 | 2021-2025 | |
| Lilly USA, LLC | $720.36 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Ucb, INC. | $546.74 | 2021-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $471.34 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $419.63 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $415.63 | 2021-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $389.70 | 2021-2025 | Nemluvio, Aklief |
| Amgen INC. | $344.72 | 2021-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $275.87 | 2023-2025 | Zoryve |
| Genzyme Corporation | $227.67 | 2022-2025 | |
| Dermavant Sciences, INC. | $201.75 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $156.18 | 2021-2025 | Jublia, Cabtreo, Siliq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $131.26 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $94.99 | 2025 | |
| Journey Medical Corporation | $89.77 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $59.71 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $58.74 | 2021-2022 | |
| Botanix Sb INC | $53.26 | 2025 | Sofdra |
| Leo Pharma INC. | $52.34 | 2024-2025 | Adbry, Anzupgo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.58 | 2022-2025 | Spevigo |
| Epi Health, LLC | $42.73 | 2021 | |
| Mallinckrodt Hospital Products INC. | $36.06 | 2025 | Acthar |
| Nabriva Therapeutics, Plc | $27.72 | 2022 | |
| Lnhc, INC | $18.47 | 2025 | Zelsuvmi |
| Genentech USA, INC. | $15.02 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.39 | 2022 | |
| Kyowa Kirin, INC. | $12.66 | 2021 | |
| Organon LLC | $11.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hislop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.